Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug
Status:
Terminated
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy of Rimonabant (SR141716)
compared to placebo on change in HbA1c and on relative change in body weight over 52 weeks in
obese type 2 diabetic patients on monotherapy inadequately controlled with oral anti-diabetic
drug (sulfonylurea or α-glucosidase inhibitor).
The secondary objectives are:
- To evaluate the effect of Rimonabant compared to placebo on other parameters related to
the glucose control, waist circumference, Body Mass Index and metabolic parameters;
- To evaluate the safety and tolerability of Rimonabant compared to placebo;
- To evaluate the pharmacokinetics of Rimonabant.